ICICI Prudential Mutual Fund Reduces Stake to 4.93% in V-Guard
V-Guard ICICI Prudential Mutual Fund Stake Sale
ICICI Prudential Mutual Fund disclosed a net disposal of 91,83,134 equity shares of V-Guard Industries Limited through open market transactions.
The filing stated that the net disposal was made during the period from January 20, 2026, to August 17, 2026. The disclosure was submitted under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
V-Guard Shareholding Impact
Before the disposal, ICICI Prudential Mutual Fund held 3,07,28,299 shares of V-Guard Industries, representing 7.04% of the company's total share capital.
Following the net disposal of 91,83,134 shares, the fund's holding declined to 2,15,45,165 shares, representing 4.93% of the company's total share capital. This represents a decrease of 2.11 percentage points in its shareholding.
On a diluted share capital basis, the fund's holding declined from 6.96% before the disposal to 4.88% after the disposal.
V-Guard Share Capital and Regulatory Disclosure
The disclosure was made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
ICICI Prudential Mutual Fund stated that its investment in V-Guard Industries is for investment purposes and not with the objective of seeking or influencing control over the company.
The filing also noted that V-Guard's share capital increased compared with the previous filing date of January 20, 2026.
V-Guard ICICI Prudential Stake Sale Highlights
- Investor: ICICI Prudential Mutual Fund.
- Shares Held Before Disposal: 3,07,28,299 shares.
- Holding Before Disposal: 7.04% of total share capital.
- Shares Disposed: 91,83,134 shares.
- Transaction Type: Open market transaction.
- Transaction Period: January 20, 2026, to August 17, 2026.
- Shares Held After Disposal: 2,15,45,165 shares.
- Holding After Disposal: 4.93% of total share capital.
- Change in Holding: Decrease of 2.11 percentage points.
- Diluted Holding Before Disposal: 6.96%.
- Diluted Holding After Disposal: 4.88%.
- Total Share Capital After Disposal: 43,68,91,055 shares.
- Investment Objective: The fund stated that the holding is for investment purposes and not for seeking or influencing control.
- Regulatory Disclosure: Disclosure made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
What to Watch Next
- Investors may track whether ICICI Prudential Mutual Fund makes any further purchases or sales of V-Guard shares.
- They may monitor future shareholding disclosures to see whether the fund's stake changes further.
- Investors may also track V-Guard's financial performance and business developments alongside changes in institutional ownership.
Disclaimer
Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Choice Equity Broking Private Limited: SEBI Reg No. Broking - INZ000160131 ( BSE - 3299 ) | ( NSE - 13773 ) | ( MSEI - 73200 ) | ( MCX - 40585 ) | ( NCDEX - 01006 ). Depository Participant SEBI Reg. No. - IN - DP - 84 - 2015, DP ID CDSL - 12066900, NSDL ID - IN301895. Research Analyst - INH000000222 (CIN. NO.: U65999MH2010PTC198714)
Other News
Go Colors Promoter Rahul Saraogi Pledges 16.25 Lakh Shares
Rahul Saroagi, a promoter of Go Fashion (India) Limited, has pledged 16,25,000 equity shares of the company for personal borrowings. The pledge was created in favour of Bajaj Financial Securities Limited on August 13, 2026, and was disclosed to the stock exchanges on August 18, 2026.
Bizotic Commercial Allots 4.82 Crore Bonus Shares in 5:1 Ratio
Bizotic Commercial Limited has approved the allotment of 4,82,10,000 fully paid-up bonus equity shares of Rs. 10.00 each in the ratio of 5:1. The bonus shares were allotted by the Board of Directors at its meeting held on August 18, 2026, to shareholders eligible as of the record date, August 17, 2026.
Biocon Receives U.S. FDA Approval for Yesintek Autoinjector
Biocon Limited's U.S. subsidiary has received supplemental approval from the U.S. Food and Drug Administration (FDA) for Yesintek® (ustekinumab-kfce) single-dose prefilled autoinjectors. The approval covers the 45 mg/0.5 mL and 90 mg/ml presentations and provides an additional delivery option for patients receiving treatment for chronic autoimmune conditions.